Standardized mortality ratios by times since hematopoietic cell transplantation
Disease categories . | Observed events . | SMR (95% CI) . |
|---|---|---|
| All diagnoses, y from HCT | ||
| 2 to 5; N = 307 | 192 | 54.8 (47.3-62.9) |
| 6 to 10; N = 363 | 51 | 5.1 (3.8-6.6) |
| 11 or more; N = 184 | 8 | 1.7 (0.7-3.0) |
| Standard risk of relapse, y from HCT | ||
| 2 to 5; n = 163 | 86 | 37.8 (30.2-46.2) |
| 6 to 10; n = 218 | 28 | 4.5 (2.9-6.3) |
| 11 or more; n = 117 | 3 | 1.1 (0.2-2.8) |
| High risk of relapse, y from HCT | ||
| 2 to 5; n = 143 | 105 | 85.8 (70.2-102.9) |
| 6 to 10; n = 144 | 23 | 5.9 (3.8-8.7) |
| 11 or more; n = 67 | 5 | 2.3 (0.7-4.8) |
| Acute myeloid leukemia, y from HCT | ||
| 2 to 5; n = 39 | 16 | 27.0 (15.4-41.9) |
| 6 to 10; n = 74 | 7 | 3.4 (1.4-6.5) |
| 11 or more; n = 45 | 1 | 0.9 (0-3.7) |
| Non-Hodgkin lymphoma, y from HCT | ||
| 2 to 5; n = 145 | 84 | 34.9 (27.8-42.7) |
| 6 to 10; n = 181 | 25 | 3.9 (2.5-5.6) |
| 11 or more; n = 66 | 4 | 1.6 (0.4-3.6) |
| Hodgkin disease, y from HCT | ||
| 2 to 5; n = 102 | 73 | 151.1 (118.5-187.8) |
| 6 to 10; n = 98 | 15 | 10.2 (5.7-16.0) |
| 11 or more; n = 45 | 2 | 1.9 (0.2-5.5) |
| Acute lymphoblastic leukemia, y from HCT | ||
| 2 to 5; n = 21 | 19 | 1004.0 (603.3-1506.2) |
| 6 to 10; n = 10 | 4 | 26.5 (6.9-58.9) |
| 11 or more; n = 28 | 1 | 4.2 (0.0-16.6) |
Disease categories . | Observed events . | SMR (95% CI) . |
|---|---|---|
| All diagnoses, y from HCT | ||
| 2 to 5; N = 307 | 192 | 54.8 (47.3-62.9) |
| 6 to 10; N = 363 | 51 | 5.1 (3.8-6.6) |
| 11 or more; N = 184 | 8 | 1.7 (0.7-3.0) |
| Standard risk of relapse, y from HCT | ||
| 2 to 5; n = 163 | 86 | 37.8 (30.2-46.2) |
| 6 to 10; n = 218 | 28 | 4.5 (2.9-6.3) |
| 11 or more; n = 117 | 3 | 1.1 (0.2-2.8) |
| High risk of relapse, y from HCT | ||
| 2 to 5; n = 143 | 105 | 85.8 (70.2-102.9) |
| 6 to 10; n = 144 | 23 | 5.9 (3.8-8.7) |
| 11 or more; n = 67 | 5 | 2.3 (0.7-4.8) |
| Acute myeloid leukemia, y from HCT | ||
| 2 to 5; n = 39 | 16 | 27.0 (15.4-41.9) |
| 6 to 10; n = 74 | 7 | 3.4 (1.4-6.5) |
| 11 or more; n = 45 | 1 | 0.9 (0-3.7) |
| Non-Hodgkin lymphoma, y from HCT | ||
| 2 to 5; n = 145 | 84 | 34.9 (27.8-42.7) |
| 6 to 10; n = 181 | 25 | 3.9 (2.5-5.6) |
| 11 or more; n = 66 | 4 | 1.6 (0.4-3.6) |
| Hodgkin disease, y from HCT | ||
| 2 to 5; n = 102 | 73 | 151.1 (118.5-187.8) |
| 6 to 10; n = 98 | 15 | 10.2 (5.7-16.0) |
| 11 or more; n = 45 | 2 | 1.9 (0.2-5.5) |
| Acute lymphoblastic leukemia, y from HCT | ||
| 2 to 5; n = 21 | 19 | 1004.0 (603.3-1506.2) |
| 6 to 10; n = 10 | 4 | 26.5 (6.9-58.9) |
| 11 or more; n = 28 | 1 | 4.2 (0.0-16.6) |